GRI Bio (GRI) to Release Quarterly Earnings on Thursday

GRI Bio (NASDAQ:GRI) is anticipated to announce its earnings results before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($6.80) per share for the quarter.

GRI Bio Stock Performance

GRI Bio stock opened at $8.06 on Tuesday. GRI Bio has a 1 year low of $5.12 and a 1 year high of $176.80. The firm’s 50-day moving average is $8.79 and its 200-day moving average is $10.62. The company has a market cap of $4.23 million, a P/E ratio of -0.70 and a beta of -2.10.

Analyst Ratings Changes

GRI has been the subject of several recent research reports. HC Wainwright assumed coverage on GRI Bio in a report on Monday, December 9th. They set a “buy” rating and a $170.00 target price for the company. Ascendiant Capital Markets upped their price target on shares of GRI Bio from $204.00 to $221.00 and gave the stock a “buy” rating in a research report on Thursday, December 5th.

About GRI Bio

GRI Bio, Inc, a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development.